

How to submit prior authorization requests for medical benefit drugs

For Blue Cross commercial and BCN commercial

Revised May 2025

Follow these steps to submit prior authorization requests when prescribing most drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Note: The information below doesn't apply to oncology medical benefit drugs.

Michigan prescribers

To submit prior authorization requests electronically:

- 1. Log in to our provider portal (<u>availity.com</u>*).
- 2. Click Payer Spaces on the menu bar and click the BCBSM and BCN logo.
- 3. Click the Medical/Pharm Drug Benefit Prior Auth (Commercial) tile on the Applications tab.
- 4. In the Medical and Pharmacy Drug PA Portal, click the Authorization menu and select Add New.
- 5. Enter the member's last name, date of birth, subscriber ID and authorization start date.
- 6. Click Search and then select the appropriate member in the member list.
- 7. Complete all required fields and submit the request.

If you're registered for Availity Essentials[™] but aren't able to access it, submit the prior authorization request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Non-Michigan prescribers

When submitting prior authorization requests, prescribers located outside of Michigan should complete the appropriate steps on the <u>Getting Started</u> page on **ereferrals.bcbsm.com**. Look in the *Submit prior authorization requests* section.

If a non-Michigan prescriber is unable to submit a prior authorization request using the instructions on the webpage, submit the request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Information about the Medical and Pharmacy Drug PA Portal

To help you learn how to use the Medical and Pharmacy Drug PA Portal, view a recorded demo by going to Blue Cross and BCN's Provider Training site, searching on *drugs* and launching the *Medical and Pharmacy Drug PA Portal Overview*.

For detailed information about accessing the Provider Training site, see the "Online training" section of the Training Tools page on **ereferrals.bcbsm.com**.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form Cinqair® (reslizumab) HCPCS CODE: J2786



This form is to be used by participating physicians to obtain coverage for Cinqair[®]. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

and oct violing c	in the Medical Brug Helpuesk at 1-000-401-0000 for assistance.		
	PATIENT INFORMATION	PHYSICIAN INFORMATION	
Name		Name	
ID Number		Specialty	
D.O.B.	☐Male ☐Female	Address	
Weight (kg): Date recorded:		
Diagnosis		City /State/Zip	
Drug Name Cinqair		Phone/Fax: P: () - F: () -	
Dose and Quantity		NPI	
Directions		Contact Person	
Date of Service(s)		Contact Person Phone / Ext.	
STEP 1:	DISEASE STATE IN	NFORMATION	
1. Is this	request for:	d therapy:	
2. Site o	f administration? Provider office/Home infusion Other: Reason for Hospital	Outpatient administration:	
3. Pleas	e specify location of administration if hospital outpatient infusion:		
4. Pleas	se provide the NPI number for the place of administration:		
	tion AND Continuation of therapy: Please check the patient's diagnosis: Severe eosinophilic asthma (EA) Other:		
C.	What is the patient's blood eosinophil level at the initiation of therapy in cells/micro Which treatment(s) did not adequately control the patient's EA after a trial of at lea Systemic corticosteroid: High dose inhaled corticosteroids: Long acting beta2-agonist: Leukotriene receptor antagonist: Combination asthma inhaler with a HIGH dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long Combination asthma inhaler with a MEDIUM dose corticosteroid and a long	Date: Start: End: acting beta agonist: Date: Start: End: Date: Start: End: Date: Start: End: Date: Start: End:	
d.		nd experienced treatment failure, intolerance, or contraindication the requested indication. Tezspire Other:	
e.	Is the patient currently receiving and will continue to receive a standard of care recomment:	gimen for their diagnosis with Cinqair?	
f.	Will the patient be using Cinqair in combination with other biologic asthma agents	• • •	
6. Conti	inuation request: (please answer above questions as well): Cinqair start date: _ a. Have the patient's signs and symptoms improved with Cinqair? Yes No, Comment:		
Please add any ot	ther supporting medical information necessary for our review		
	Coverage will not be provided if the prescribing physician's	s signature and date are not reflected on this document.	
☐ Request for expe	edited review: I certify that applying the standard review time frame may seriously jeopardize the life me Physician Signature	e or health of the member or the member's ability to regain maximum function Date	
Step 2 Checklist	☐ Form Completely Filled Out ☐ Attach Chart Notes	☐ Attach Diagnostic Tests	
Step 3 Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320	